Search Results 111-120 of 14765 for Proto-oncogene

1. Mayo GBM PDX Line Data - Translational Neuro-Oncology: Jann N. Sarkaria - Mayo Clinic Research

   Mayo Clinic Brain Tumor Patient-Derived Xenograft National Resource: Growth characteristics, invasiveness, subtypes, tissue microarray & clinical data.

2. Sacituzumab Tirumotecan (MK-2870) In Combination With Pembrolizumab Versus Pembrolizumab Alone In Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) - Mayo Clinic

   ... proto-oncogene tyrosine-protein kinase ROS (ROS1-) directed therapy is not indicated as primary therapy * Provided tumor tissue that demonstrates programmed ...

3. Study Of Pazopanib In The Treatment Of Osteosarcoma Metastatic To The Lung - Mayo Clinic

   The purpose of this study is to determine the 4-month Progression-Free Survival (PFS), with demonstrated increase in tumor doubling time, of eligible subjects ...

4. Minibeam Radiation Therapy With Tungsten Slit Collimator For The Treatment Of Recurrent Or Metastatic Skin Or Soft Tissue Tumors - Mayo Clinic

   * Treatment with a B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitor, monoclonal antibodies targeting vascular endothelial growth factor (VEGF) ...

5. Degradation of Alpha-Synuclein - Neurobiology of Parkinson's Disease Laboratory - Mayo Clinic Research

   The ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway are two of the most important mechanisms to repair or remove abnormal proteins.

6. https://www.mayoclinic.org/spanish_patient_consumer_web.xml

7. https://www.mayoclinic.org/patient_consumer_web.xml

8. Funding - Research - Mayo Clinic Research

   View funding sources for the Epigenetic Etiology of Human Disease Lab led by Keith Robertson, Ph.D., at Mayo Clinic's campus in Minnesota.

9. Study Of Datopotamab Deruxtecan (Dato-DXd) In Combination With Durvalumab And Carboplatin For First-Line Treatment Of Patients With Advanced NSCLC Without Actionable Genomic Alterations - Mayo Clinic

   driver oncogenes with approved therapies (actionable genomic alterations). - ECOG PS of 0 or 1 - Archival tumour tissue collected prior to signing of ICF - ...

10. Publications - Vanessa E. Torbenson, M.D. - Mayo Clinic

    McCarter AR, Theiler RN, Branda ME, Smith RM, Sharpe EE, Torbenson VE. The obstetrics comorbidity index as a predictive tool for risk-appropriate maternal ...